Marc Tessier-Lavigne, Director at Denali Therapeutics Inc. (DNLI), sold 6,376 shares at $60.08 ($383K) on 2021-05-03, disclosed to the SEC on 2021-05-05.
Open-market sale of $383k DNLI by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $60.08 | 3,139 | $189K | 49.2% |
| 2 | $60.08 | 3,139 | $189K | 49.2% |
| 3 | $61.20 | 98 | $6K | 1.6% |
| Total | $60.10 avg | 6,376 | $383K | 100% |
| Filing → |
| REGN | SELL | 2022-10-03 | $10.2M | — | Filing → |
| DNLI | SELL | 2022-09-30 | $1.2M | — | Filing → |
| DNLI | SELL | 2022-08-25 | $632K | — | Filing → |